FOR IMMEDIATE RELEASE
LABOPHARM COMMENTS ON JUDGMENT IN PURDUE APPEAL OF DECISION
RELATING TO PATENTS
LAVAL, Québec (June 4, 2010) – Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today commented on the outcome of the
appeal by Purdue Pharma Products L.P. and the cross-appeal by Par Pharmaceutical Companies, Inc. of the decision of the
United States District Court for the District of Delaware (the Court) in August 2009 on patent-infringement litigation initiated by
Purdue against Par relating to Ultram® ER ( tramadol hydrochloride extended-release tablets).
In its decision of August 2009, the Court entered judgment in favor of Purdue and against Par on the issue of infringement and
rejected Par's claim that the patents were unenforceable for inequitable conduct. The Court, however, entered judgment in favor
of Par and against Purdue on the issue of validity, citing obviousness. On June 3, 2010, the United States Court of Appeals for
the Federal Circuit entered judgment upholding the lower court’s original decision.
The August 2009 judgment permitted Par to market its generic formulation of Ultram ER in the U.S. following receipt of final
regulatory approval from the U.S. Food and Drug Administration. Labopharm’s once-daily tramadol product, RYZOLT™, is
marketed in the U.S. by Purdue, however, Ultram® ER, and therefore any generic version of it, is not therapeutically equivalent
(A/B rated) to RYZOLT™, and cannot be substituted for RYZOLT™.
About Labopharm Inc.
Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the
performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead
product, a unique once-daily formulation of tramadol, is now available in 19 countries around the world, including the U.S.,
Canada, major European markets and Australia. Its second product, OLEPTRO™, a novel formulation of trazodone for the
treatment of major dep